Weight

Thousands of people begin receiving their first deliveries of once-a-day medication made by Novo NordiskBusiness live – latest updatesA once-a-day Wegovy weight-loss pill has gone on sale at high street and online pharmacies in the UK, but is not yet available on the NHS.Thousands of people began receiving their first deliveries of the pill, made by the Danish drugmaker Novo Nordisk, on Monday. It contains the same active GLP-1 ingredient as the Wegovy jab, semaglutide, and is similarly effective, according to studies. Continue reading...

• Mistral AI is seeking $3.5 billion in funding to advance its goals of European AI sovereignty and enterprise-grade technology. • The company has promised to release a new open weights model this summer to compete in the evolving AI landscape. • This strategic move comes amid rising demands for sovereign technology and follows disruptions to other models, such as those from Anthropic.

• Lizzo appeared at the 2026 BET Awards wearing a sparkling sheer gown, drawing significant public attention to her dramatic weight loss. • The appearance serves as a public showcase of the singer's ongoing body transformation journey. • This event highlights Lizzo's evolving relationship with her public image and her choice to share her health journey through high-profile fashion statements.

Regulator approval means patients who meet criteria such as having obesity will be able to purchase pills with private prescriptionPatients will soon be able to buy the Wegovy weight-loss pill, the medicines regulator announced today.It is the first GLP-1 receptor agonist tablet for weight-loss to be approved by the Medicines and Healthcare products Regulatory Agency (MHRA), making the UK the third country to authorise the pills, behind the US and the United Arab Emirates. Continue reading...

• Shoptalk Europe unveiled five major predictions for the future of European retail during its 2026 event in Barcelona. • The forecast identifies AI shopping agents, the rise of weight-loss drugs, a "recommerce boom," personalized physical stores, and revamped supply chain planning as primary drivers of change. • These trends are expected to fundamentally reshape the retail industry over the next decade, impacting how consumers shop and how businesses operate.

New research suggests GLP-1 users are buying fewer snacks and treats such as crisps and chocolateBusiness live – latest updatesWeight-loss drugs are saving users’ households more than £400 a year on grocery bills, according to new research, which found use of GLP-1s has nearly tripled in the past two years to 1.9 million adults.Just more than 6.3% of households in Great Britain now include at least one GLP-1 user, according to the survey from Worldpanel by Numerator. This marks a sharp rise from 4.1% of households in 2025 and 2.3% in 2024. Continue reading...

Price of dairy product has risen fivefold after users of GLP-1 medications advised to increase protein consumptionThe growing popularity of weight-loss drugs has fuelled global demand for whey protein, sparking concerns among industry experts over a potential shortage.The price of whey has risen fivefold to record levels as companies race to secure supplies amid a boom driven by growing use of GLP-1 drugs, such as Mounjaro, which often require higher protein intake to preserve muscle mass. Continue reading...

Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo.The triple hormone drug mimics three gut hormones that help control your appetite, blood sugar and metabolism: GLP-1, GIP and glucagon. Unlike other diabetes medications such as Ozempic and Wegovy, which primarily target the GLP-1 pathway to suppress appetite, or Mounjaro, which contains GLP-1 plus GIP to control blood-sugar levels, retatrutide also engages the glucagon receptor, which helps increase energy expenditure. Continue reading...

• South Korean stocks plummeted 4% on Friday, driven by a sharp decline in tech heavyweights following a sell-off of AI-linked names on Wall Street. • The downturn extended across Asia-Pacific markets, with Hong Kong's Hang Seng index dropping 0.46% and the CSI 300 declining 0.29%. • This shift reflects a broader market rotation away from chip stocks, which paradoxically helped the Dow Jones Industrial Average reach a record close.

Patients with knee arthritis who took medications for at least three years at reduced risk of needing surgeryTaking weight-loss drugs for at least three years could prevent thousands of knee replacements a year, research suggests.Globally, more than 500 million people have osteoarthritis. Knee arthritis is the most common form, affecting about 14 million people in the US and more than 5 million in the UK. Many will require knee surgery. In the UK more than 120,000 knee replacements are carried out every year. Continue reading...

• Increased geopolitical threats from the east and west have made EU membership more appealing to non-member states seeking stability and security. • Recent developments include a security and defence partnership signed with Brussels in March, as well as growing interest in joining from Norway's main conservative opposition party. • Reports indicate that Faroe Islanders may be reconsidering their pursuit of independence from EU member Denmark.

Two men arrested in raid in which 12,000 doses of unlicensed weight-loss medicines recoveredA country estate near Northampton has become the centre of the largest-ever seizure of unlicensed weight-loss medicines in the UK.Two men, both aged 29, were arrested during a raid in which the Medicines and Healthcare products Regulatory Agency (MHRA) recovered about 12,000 doses of unlicensed weight-loss medicines. Continue reading...

Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugsA new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced Thursday.The Indiana-based pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss of 70.3lbs (28.3%) over 80 weeks among participants receiving the 12mg dose, with 45.3% achieving at least 30% weight loss. Continue reading...

Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesityFaced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and public employees have now started to restrict or eliminate coverage.The pullback stems from the dramatic increase in public spending on drugs such as Ozempic and Wegovy in recent years. Continue reading...

The 79th edition of the film festival will see work by Pedro Almodóvar, Hirokazu Kore-eda and László Nemes considered for the coveted Palme d’OrGillian Anderson, Rami Malek, Cara Delevingne and John Travolta are expected to walk the red carpet at Cannes this year, as the world’s most influential film festival unveiled an auteur-heavy lineup for its 79th edition.Competing for the coveted Palme d’Or will be new films by heavyweights Pedro Almodóvar, Hirokazu Kore-eda, Paweł Pawlikowski, László Nemes and Asghar Farhadi. Continue reading...

Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s WegovyThe US Food and Drug Administration (FDA) gave the green light on Wednesday to a new oral weight-loss medication developed by the Indianapolis-based pharmaceutical company Eli Lilly.Known as orforglipron or brand name Foundayo, the once-daily tablet becomes the second GLP-1 drug in pill form to hit the market in a short span of time, arriving after Novo Nordisk’s Wegovy pill received approval in December. Continue reading...

After a 1,088-day wait, a jury acquitted the man Nichols accused. She describes her experience of the system as a complainant – and explains why she went publicWarning: this article contains graphic testimonyCharlotte Nichols on her rape trial ordeal – podcastSitting in the House of Commons, waiting for the speaker to call her name last week, the MP Charlotte Nichols was doing breathing exercises to try to keep calm. “I was just trying to get myself into the headspace where I could say what I wanted to say without either completely garbling it or just crying or bottling it at the last minute.”She didn’t bottle it. She stood up, asked MPs to be gentle with her, and then went public with her biggest secret. Continue reading...